BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27849442)

  • 1. To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population.
    De Andrés F; Terán S; Hernández F; Terán E; LLerena A
    OMICS; 2016 Dec; 20(12):699-710. PubMed ID: 27849442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
    de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A
    OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.
    Dorado P; González I; Naranjo ME; de Andrés F; Peñas-Lledó EM; Calzadilla LR; LLerena A
    OMICS; 2017 Jan; 21(1):17-26. PubMed ID: 28271978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population.
    de Andrés F; Altamirano-Tinoco C; Ramírez-Roa R; Montes-Mondragón CF; Dorado P; Peñas-Lledó EM; LLerena A
    Pharmacogenomics J; 2021 Apr; 21(2):140-151. PubMed ID: 33024249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplex Phenotyping for Systems Medicine: A One-Point Optimized Practical Sampling Strategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 Activities Using a Cocktail Approach.
    de Andrés F; Terán S; Bovera M; Fariñas H; Terán E; LLerena A
    OMICS; 2016 Feb; 20(2):88-96. PubMed ID: 26600202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.
    LLerena A; Naranjo ME; Rodrigues-Soares F; Penas-LLedó EM; Fariñas H; Tarazona-Santos E
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1569-83. PubMed ID: 25316321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
    Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
    Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.
    Temesvári M; Kóbori L; Paulik J; Sárváry E; Belic A; Monostory K
    J Pharmacol Exp Ther; 2012 Apr; 341(1):294-305. PubMed ID: 22262920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
    Shah RR; Smith RL
    Drug Metab Dispos; 2015 Mar; 43(3):400-10. PubMed ID: 25519488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization CYP1A2, CYP2C9, CYP2C19 and CYP2D6 Polymorphisms Using HRMA in Psychiatry Patients with Schizophrenia and Bipolar Disease for Personalized Medicine.
    Yenilmez ED; Tamam L; Karaytug O; Tuli A
    Comb Chem High Throughput Screen; 2018; 21(5):374-380. PubMed ID: 29921201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs).
    Kuhlmann JB; Wensing G; Kuhlmann J
    Int J Clin Pharmacol Ther; 2014 Feb; 52(2):143-50. PubMed ID: 24361088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications of Psychotropic and Pain Medications in an Ultrarapid Metabolizer Patient at the Upper 1% of Cytochrome P450 (CYP450) Function Quantified by Combinatorial CYP450 Genotyping.
    Ruaño G; Larsen K; Kocherla M; Graydon JS; Kost J
    J Pain Palliat Care Pharmacother; 2017 Jun; 31(2):126-138. PubMed ID: 28506184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
    Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
    Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
    Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
    Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP450 genotype and pharmacogenetic association studies: a critical appraisal.
    Shah RR; Gaedigk A; LLerena A; Eichelbaum M; Stingl J; Smith RL
    Pharmacogenomics; 2016 Feb; 17(3):259-75. PubMed ID: 26780308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail.
    de Andrés F; Sosa-Macías M; Lazalde-Ramos BP; Naranjo ME; Tarazona-Santos E; Llerena A;
    Drug Metabol Drug Interact; 2013; 28(3):135-46. PubMed ID: 23787463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex.
    Hatta FH; Lundblad M; Ramsjo M; Kang JH; Roh HK; Bertilsson L; Eliasson E; Aklillu E
    OMICS; 2015 Jun; 19(6):346-53. PubMed ID: 25977991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.